Salute e Benessere

Groupe Casino: RELEASE OF THE HALF YEAR 2024 RESULTS PRESENTATION

The Group has released its half year 2024 results presentation on its website. It is available at this link: https://www.groupe-casino.fr/wp-content/uploads/2024/07/20240731-Presentation-H1-2024-EN.pdf Analyst and investor contactsChristopher Welton+33 (0)1 53 65 64 17cwelton.exterieur@groupe-casino.fr Charlotte Izabel+33 (0)1 53 70 51 29cizabel@groupe-casino.frInvestor Relations+33 (0)1 53 65 24 17IR_Casino@groupe-casino.fr Press...
Nasdaq GlobeNewswire
31/07/2024

PureHealth Achieves AED 1.0 billion Net Profit in 1H 2024; EBITDA Soars to AED…

Revenue from Hospitals grew 83% y-o-y to AED 9.6 billion in H1 2024, primarily driven by the contributions generated from the Group's acquisitions of Sheikh Shakhbout Medical City (SSMC) and Circle Health Group during the period. The segment's revenue was also supported by higher patient volumes (OP up 17% y-o-y, IP up 43% y-o-y, and ED up 43% y-o-y)1 along with an 11% increase in overall bed occupancy to 72%, as well as the addition of the National Rehabilitation Center (NRC) to PureHealth's…
PR Newswire
31/07/2024

Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company…

Dr. Kronenberg brings 25 years of legal experience, with 20 years in the pharmaceutical industry Oliver Strub appointed as Head of CompliancePratteln, Switzerland, July 31, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Board of Directors has appointed Dr. Oliver P. Kronenberg as Chief Legal Officer and Corporate Secretary of Santhera Pharmaceuticals AG, effective August 1, 2024. As a member of the executive management team, Dr. Oliver P. Kronenberg will lead the...
Nasdaq GlobeNewswire
31/07/2024

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for…

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market...
Nasdaq GlobeNewswire
30/07/2024

Long-term lecanemab data show increased patient benefit with maintained safety…

Highlights of the presentations included: Highlights of the presentations included: "Long-term data for lecanemab which our partner Eisai has presented today are very impressive. It shows that the patient benefit of lecanemab continues to increase over time, which is exactly what is expected from a disease modifying treatment. In addition, the safety profile continues to be in line with what we saw in the phase three study," saidGunilla Osswald, CEO at BioArctic. "It is also…
PR Newswire
30/07/2024

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and…

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT ToddlersDBV...
Nasdaq GlobeNewswire
30/07/2024

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in…

The interim analysis evaluated six-month data from 74 patients enrolled in the trial, assessing the likelihood of the trial achieving one of its co-primary endpoints, specifically the preservation of endogenous insulin-producing capacity measured as stimulated C-peptide. The DSMB's recommendation is based on the data observed to date, indicating that the trial is on track and has the potential to meet its objectives. The interim analysis evaluated six-month data from 74 patients enrolled in…
PR Newswire
30/07/2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

AggregatedpresentationbydayandbymarketPurchases of own shares from July 22th to 26th, 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1122/07/2024FR00102591504 826110,5421XPARIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
30/07/2024

Casino Group: Press release - H1 2024

FIRST-HALF 2024 The transformation of the New Casino is underway Financial results downgraded by a damaging legacy and the context of restructuringRestructuring projects well under wayStreamlining of the store network: closures, conversions to franchises and rational expansionSale of hypermarkets and supermarkets, the main source of the Group's historic lossesReorganisation of the Group's head offices and logistics at Distribution Casino FranceAgreement to sell Codim...
Nasdaq GlobeNewswire
30/07/2024

H1 2024 Results - Focus-27 strategic plan on track with timely execution of the…

Press Release Paris, 30th July 2024 Net Sales down 9.6% year-on-year – Core EBITDA margin at 10.6%Accelerated commercial momentum with clients other than Sanofi, with Net Sales up 2.9%, excluding the Brindisi site, where production was temporarily suspendedEnhanced effectiveness across the entire organization, with sizeable improvements in industrial efficiencies€10 million Free Cash Flow before financing, driven by strengthened financial disciplineFY 2024...
Nasdaq GlobeNewswire
30/07/2024

eClinical Solutions Market worth $22.1 billion by 2029 driven by Rising Chronic…

Browse in-depth TOC on "eClinical Solutions Market"317 - Tables54 - Figures244 - Pages Browse in-depth TOC on "eClinical Solutions Market" 317 - Tables 54 - Figures 244 - Pages Medidata (A Dassault Systèmes Company): Leader in End-to-End Clinical Data Management Medidata excels in global clinical data capture and management with extensive functionality tailored for diverse clinical study needs. The company's robust market position is reinforced by its comprehensive organic...
PR Newswire
30/07/2024

Digital Health Market to Reach USD 881 Billion in 2031 on the Back of Growing…

Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/digital-health-market Digital Health Market Overview: Segments covered in Digital Health Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/digital-health-market Enhanced Internet Connectivity Estimated to Boost Demand for Digital Health for Telehealth Technology Growing penetration of digital...
PR Newswire
30/07/2024

Biosimilars Market Likely to Attain Valuation of USD 92 Billion by 2031 As…

Download a detailed overview:https://www.skyquestt.com/sample-request/biosimilars-market Download a detailed overview: https://www.skyquestt.com/sample-request/biosimilars-market Biosimilars Market Overview: Segments covered in Biosimilars Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/biosimilars-market Oncology Projected to Spearhead Biosimilar Demand Owing to Increasing Need for Novel Cancer Treatments...
PR Newswire
30/07/2024

Dental Membrane and Bone Graft Substitutes Market to Reach US$ 1.3 Billion by…

The dental membrane and bone graft substitutes market stood at US$ 650.8 Mn in 2022 and is expected to record a CAGR of 7.7% from 2023 to 2031, as per Transparency Market Research (TMR). The dental membrane and bone graft substitutes market stood at US$ 650.8 Mn in 2022 and is expected to record aCAGR of 7.7%from2023 to 2031, as perTransparency Market Research (TMR). Bone grafting is a surgical procedure practiced to repair lost or damaged bones that are located below...
PR Newswire
30/07/2024

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031-…

The clean beauty movement places the highest premium on sustainability, safety, and transparency in the skincare industry. People can take better care of their physical appearance and have a smaller environmental impact when they appreciate clean beauty. Everyone may contribute to the sustainable beauty revolution in the future, which promises to be a fascinating time of inventions and improvements. The clean beauty movement places the highest premium on sustainability, safety, and…
PR Newswire
30/07/2024

Nocturia Market to Reach US$ 8.5 Billion by 2034, Fueled by the Integration of…

A significant trend is the increased focus on patient-centric care. Healthcare providers and pharmaceutical companies are prioritizing patient education and support programs to enhance understanding and management of nocturia. This approach aims to improve treatment adherence and patient outcomes by empowering individuals with the knowledge and tools to manage their condition effectively. A significant trend is the increased focus on patient-centric care. Healthcare providers and…
PR Newswire
30/07/2024

Connext Successfully Administers First Dose of CNT201 for Dupuytren's…

Dupuytren's contracture is a debilitating condition characterized by the fibrosis of the fascia between the skin and tendons of the palm due to collagen buildup, causing fingers to become permanently bent and significantly impairing patients' quality of life. Currently, there is no fundamental cure for this condition. Treatments primarily involve surgical interventions like fasciectomy to alleviate symptoms, although non-surgical methods, such as localized injections of collagenase, have shown…
PR Newswire
30/07/2024

Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision…

i-Ome Cancer marks a significant leap forward in immunoproteomics, providing a rapid and cost-effective approach to characterize the immune system's response to cancer. Cancer is closely associated with protein alterations, which can stimulate the production of autoantibodies. i-Ome Cancer capitalizes on this relationship, enabling the direct identification of disease-associated proteins, offering crucial insights into this devastating disease and its treatment. i-Ome Cancermarks a...
PR Newswire
30/07/2024

ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of…

ALISO VIEJO, Calif., July 30, 2024 /PRNewswire/ -- ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) for its ViaLase® Laser* for the treatment of adult patients with primary open-angle glaucoma (POAG). ALISO VIEJO, Calif.,July 30, 2024/PRNewswire/ -- ViaLase, Inc ., a clinical-stage medical...
PR Newswire
30/07/2024

Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said, "Achieving this threshold is a significant milestone in the history of Piramal Pharma Solutions. For many years, our organizational strategies and tactics have focused on building the expertise and capabilities required to fully support innovator work. This breakthrough validates our efforts and secures our position as an innovator CDMO that support customers in their quest to bring new, patient-centric medicines to…
PR Newswire
30/07/2024

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers…

The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brain These tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July30, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a...
Nasdaq GlobeNewswire
30/07/2024

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call…

To access the conference call, please registerhere. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website atir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics...
Nasdaq GlobeNewswire
30/07/2024

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

GLP-1 receptor agonists, which mimic the natural hormone glucagon-like peptide released by the stomach after eating, can help people manage diabetes, lose weight and lower their risk of heart disease, stroke and kidney disease. Research in animal models of Alzheimer's disease suggests these drugs may have neuroprotective effects, reduce early forms of amyloid, normalize the brain's processing of glucose, and improve memory and learning. Liraglutide (Novo Nordisk) likely works by multiple…
PR Newswire
30/07/2024

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy…

Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab Data demonstrated a statistically significant improvement of overall response rate (“ORR”) compared to historical control in patients withanti-PD-(L)1 relapsed/refractory advanced melanoma BioNTech and Regeneron plan to present data from this trial at a forthcoming medical conference; the BNT111 program received a Fast Track...
Nasdaq GlobeNewswire
30/07/2024
Altri  Comunicati